Niemann–Pick disease type C
| Niemann–Pick disease, type C | |
|---|---|
| Other names | Niemann–Pick disease, type D |
| NPC1, the protein that is mutated in Niemann–Pick disease, type C | |
| Specialty | Endocrinology, neurology |
| Symptoms | Hepatosplenomegaly, dementia |
| Complications | Akinetic mutism, respiratory arrest |
| Usual onset | 50% by the age of 10 |
| Duration | Longer duration if symptoms begin later in life, most die by the age of 13 |
| Types | Type C1, type C2, type D (obsolete) |
| Causes | Mutations in the NPC1 and NPC2 genes |
| Risk factors | Having parents with the disease, or parents that are carriers of the disease |
| Diagnostic method | Gene sequencing |
| Differential diagnosis | Other childhood dementias |
| Prevention | Gene editing |
| Treatment | Arimoclomol, levacetylleucine, experimental treatments, and palliative care |
| Medication | Arimoclomol and levacetylleucine |
| Prognosis | Invariably fatal, duration varies |
| Frequency | 1 in 150,000 |
Niemann–Pick type C (NPC) (colloquially, "Childhood Alzheimer's") is a lysosomal storage disease associated with mutations in NPC1 and NPC2 genes. Niemann–Pick type C affects an estimated 1:150,000 people. Approximately 50% of cases present before ten years of age, but manifestations may first be recognized as late as the sixth decade. Despite its name, Niemann-Pick disease, type C has very little to do with SMPD1-associated Niemann–Pick disease, although they were once thought to be the same disease.